Douglas E. Onsi has been the CEO of Leap Therapeutics, Inc. since April 2020. He holds a Bachelor’s degree in Finance from the University of Michigan and has a solid background in finance, having previously served as Chief Financial Officer...
Douglas E. Onsi has been the CEO of Leap Therapeutics, Inc. since April 2020. He holds a Bachelor’s degree in Finance from the University of Michigan and has a solid background in finance, having previously served as Chief Financial Officer of Leap. Before joining Leap, he was a managing director at HealthCare Ventures and held various roles at Genzyme Corporation, focusing on oncology product operations and business development. His leadership style emphasizes aligning the company’s goals with shareholders' interests, which is seen in the way he guides Leap towards clinical and financial milestones. Interestingly, throughout his time at Leap, he has engaged in significant insider trading activities, reflecting his confidence in the company’s future. In 2023, he received over $1.3 million in total compensation, composed primarily of salary and bonuses based on performance metrics set by the board, which included clinical study completions and new product developments. Douglas is also noteworthy for his strategic decisions regarding stock options and has a vested interest in the company’s stock, facilitating a deep connection between executive decisions and investor returns. This approach gives him a unique perspective on leading Leap Therapeutics as it navigates the complexities of the biopharmaceutical landscape.